Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

The females in my family on my mother's side seem to develop dementia/Alzheimer's on a fairly regular basis. It seems to ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Advanced imaging, such as PET scans, are beginning to show the ability to diagnose Alzheimer’s dementia in people with early ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

From taking HRT to eating a healthy diet, Kate Muir shares some of the precautionary measures she's trying to avoid ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, ...